Protection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation

Infection and Immunity

Volumn 70, Issue 5, 2002, Pages 2375-2382

  Cenci, Elio ^a   Mencacci, Antonella ^a   Spreca, Antonio ^a   Montagnoli, Claudia ^a   Bacci, Angela ^a   Perruccio, Katia ^a   Velardi, Andrea ^a   Magliani, Walter ^a   Conti, Stefania ^a   Polonelli, Luciano ^a   Romani, Luigina ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

IDIOTYPIC ANTIBODY; KILLER TOXIN; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ALLOGENIC BONE MARROW TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DISEASE PREDISPOSITION; DRUG EFFICACY; FUNGUS GROWTH; GROWTH INHIBITION; IMMUNE RESPONSE; LUNG ASPERGILLOSIS; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ASPERGILLOSIS; BONE MARROW TRANSPLANTATION; FEMALE; HYPHAE; LUNG; LUNG DISEASES, FUNGAL; LYMPHOCYTE DEPLETION; MICE; MICE, INBRED C3H; MICE, INBRED DBA; T-LYMPHOCYTES; TRANSPLANTATION, HOMOLOGOUS;

EID: 0036122162     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/IAI.70.5.2375-2382.2002     Document Type: Article

References (47)

1. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice
2. Interactions of surfactant proteins A and D with Saccharomyces cerevisiae and Aspergillus fumigatus
3. Megadose of T-cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice
4. Invasive mold infections in allogeneic bone marrow transplant recipients
5. Glucan synthase complex of Aspergillus fumigatus
6. Therapy of mucosal candidiasis by expression of an antiidiotype in human commensal bacteria
7. Antibody and/or cell-mediated immunity, protective mechanisms in fungal disease: An ongoing dilemma or an unnecessary dispute?
8. Antibodies, killer toxins and antifungal immunoprotection, a lesson from nature?
9. Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis
10. Cytokine- and T-helper-dependent immunity in murine aspergillosis
11. Mycobactericidal activity of human natural, monoclonal, and recombinant yeast killer toxin-like antibodies
12. Killer antibodies in fungal infections
13. Invasive aspergillosis
14. Emerging targets for the development of novel antifungal therapeutics
15. Compounds active against cell walls of medically important fungi
16. Granulocyte transfusion therapy: Update on potential clinical applications
17. In situ localization of beta-glucans in the cell wall of Schizosaccharomyces pombe
18. Normal human fibroblasts express pattern recognition receptors for fungal (1→3)-βD-glucans
19. Aspergillus fumigatus and aspergillosis
20. A rapid colorimetric assay of fungal viability with the tetrazolium salt MTT
21. Protective role of lung surfactant protein D in a murine model of invasive pulmonary aspergillosis
22. Therapeutic potential of antiidiotypic single chain antibodies with yeast killer toxin activity
23. Yeast killer systems
24. Comparative study of susceptibilities of germinated and ungerminated conidia of Aspergillus fumigatus to various antifungal agents
25. Defective antifungal T-helper 1 (Th1) immunity in a murine model of allogeneic T-cell-depleted bone marrow transplantation and its restoration by treatment with TH2 cytokine antagonists
26. Absence of respiratory burst in X-linked chronic granulomatous disease mouse leads to abnormalities in both host defense and inflammatory response to Aspergillus fumigatus
27. Receptor binding and internalization of water-soluble (1→3)-beta-D-glucan biologic response modifier in two monocyte/macrophage cell lines
28. Fungal spores in lung and sputum
29. Human natural yeast killer toxin-like candidacidal antibodies
30. Production and characterization of yeast killer toxin monoclonal antibodies
31. Monoclonal yeast killer toxin-like candidacidal anti-idiotypic antibodies
32. Hemopoietic stem cell transplantation using mouse bone marrow and spleen cells fractionated by lectins
33. + T helper subset selection in mice with candidiasis
34. Colony stimulating factors in patients with fever and neutropenia
35. Infections in bone marrow transplant recipients
36. Involvement of a cell wall receptor in the mode of action of an anti-Candida toxin of Pichia anomala
37. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus
38. Host defense mechanism in Aspergillus fumigatus infections
39. Inhibitory effect of human natural yeast killer toxin-like candidacidal antibodies on Pneumocystis carinii
40. Combined treatment: Antifungal drugs with antibodies, cytokines or drugs
41. Putative virulence factors of Aspergillus fumigatus
42. Expression and identification of a laminin-binding protein in Aspergillus fumigatus conidia
43. Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells
44. Glucan-based macrophage stimulators: A review of their anti-infective potential
45. Fungal infections after bone marrow transplant
46. Killer toxin from Hansenula mrakii selectively inhibits cell wall synthesis in a sensitive yeast
47. Innate immunity and pulmonary host defense